Review



nmdar antagonist d l apv  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Tocris nmdar antagonist d l apv
    Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the <t>NMDAR</t> component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).
    Nmdar Antagonist D L Apv, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 2603 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmdar+antagonist+d+l+ap5/D-AP5/10__1523_slash_eneuro__0118___19__2019-72-8-13
    Average 96 stars, based on 2603 article reviews
    nmdar antagonist d l apv - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "Differences in GluN2B-Containing NMDA Receptors Result in Distinct Long-Term Plasticity at Ipsilateral versus Contralateral Cortico-Striatal Synapses"

    Article Title: Differences in GluN2B-Containing NMDA Receptors Result in Distinct Long-Term Plasticity at Ipsilateral versus Contralateral Cortico-Striatal Synapses

    Journal: eneuro

    doi: 10.1523/eneuro.0118-19.2019

    Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the NMDAR component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).
    Figure Legend Snippet: Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the NMDAR component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).

    Techniques Used: Functional Assay, Immunostaining, Injection, Expressing

    Figure 2. Differences in subunit composition of synaptic NMDARs between the ipsilateral and contralateral cortico-striatal pathways. A, Double tdTomato and EGFP immunostaining shows segregation of D1 and D2 MSNs in the striatum of Drd1a-tdTomato::Drd2- EGFP double transgenic mice. B, Representative NMDAR EPSCs (from C) in D1 (top) and D2 MSNs (bottom) evoked by electrical stimulation of the cortico-striatal pathway. Traces are from baseline (1), 10 min after ifenprodil (2), 10 min after TCN-201 (3), and 10 min after D,L-APV. C, Average effects of ifenprodil, TCN-201, and D,L-APV on NMDAR EPSC amplitudes (n 7, D1 MSNs; n 6, D2 MSNs; p 0.56, two-way ANOVA). D, Representative EPSCs (from E) evoked by blue light in ipsilateral (top) and contralateral (bottom) MSNs. Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). E, Average effects of ifenprodil and TCN-201 on blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.0013, two-way ANOVA). F, Average percentage of the ifenprodil-sensitive and TCN-201-sensitive components of NMDAR-mediated EPSCs. The ifenprodil- sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in ifenprodil from baseline EPSCs; the TCN-201-sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in TCN-201 from EPSCs in the presence of ifenprodil (p 0.0001, unpaired Student’s t test). G, tdTomato and GFP immunostaining shows ipsilateral Chrimson expression and contralateral Chronos expression. Scale bars: 100 m (left) and 10 m (right). H, Representative EPSCs (from I) evoked by either Chrimson-activating red light (625 nm, top) or Chronos-activating blue light (470 nm, bottom). Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). l, Average effects of ifenprodil and TCN-201 on red light-evoked and blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.028, two-way ANOVA).
    Figure Legend Snippet: Figure 2. Differences in subunit composition of synaptic NMDARs between the ipsilateral and contralateral cortico-striatal pathways. A, Double tdTomato and EGFP immunostaining shows segregation of D1 and D2 MSNs in the striatum of Drd1a-tdTomato::Drd2- EGFP double transgenic mice. B, Representative NMDAR EPSCs (from C) in D1 (top) and D2 MSNs (bottom) evoked by electrical stimulation of the cortico-striatal pathway. Traces are from baseline (1), 10 min after ifenprodil (2), 10 min after TCN-201 (3), and 10 min after D,L-APV. C, Average effects of ifenprodil, TCN-201, and D,L-APV on NMDAR EPSC amplitudes (n 7, D1 MSNs; n 6, D2 MSNs; p 0.56, two-way ANOVA). D, Representative EPSCs (from E) evoked by blue light in ipsilateral (top) and contralateral (bottom) MSNs. Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). E, Average effects of ifenprodil and TCN-201 on blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.0013, two-way ANOVA). F, Average percentage of the ifenprodil-sensitive and TCN-201-sensitive components of NMDAR-mediated EPSCs. The ifenprodil- sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in ifenprodil from baseline EPSCs; the TCN-201-sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in TCN-201 from EPSCs in the presence of ifenprodil (p 0.0001, unpaired Student’s t test). G, tdTomato and GFP immunostaining shows ipsilateral Chrimson expression and contralateral Chronos expression. Scale bars: 100 m (left) and 10 m (right). H, Representative EPSCs (from I) evoked by either Chrimson-activating red light (625 nm, top) or Chronos-activating blue light (470 nm, bottom). Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). l, Average effects of ifenprodil and TCN-201 on red light-evoked and blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.028, two-way ANOVA).

    Techniques Used: Immunostaining, Transgenic Assay, Expressing

    Related Articles

    other:

    Article Title: Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice
    Article Snippet: In order to pharmacologically isolate the NMDAR from the non-NMDAR component of LTP, the NMDAR antagonist D,L-AP5 (50 μM) (Tocris Bioscience, Minneapolis, MN) was bath applied for 30 minutes prior to HFS, continued for 5 minutes post-HFS and washed out for the remainder of recording.

    Article Title: Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice.
    Article Snippet: In order to pharmacologically isolate the NMDAR from the nonNMDAR component of LTP, the NMDAR antagonist D,L-AP5 (50 lM) (Tocris Bioscience, Minneapolis, MN) was bath applied for 30 min prior to HFS, continued for 5 min post-HFS and washed out for the remainder of recording.

    Article Title: Seizure induced synaptic plasticity alteration in hippocampus is mediated by IL-1β receptor through PI3K/Akt pathway
    Article Snippet: To measure the non-NMDAR component of LTP, the NMDAR antagonist d,l-AP5 (50 μM, Tocris Bioscience, Minneapolis, MN, USA) was applied before LTP measurement.



    Similar Products

    nmdar antagonist d l apv  (Tocris)
    96
    Tocris nmdar antagonist d l apv
    Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the <t>NMDAR</t> component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).
    Nmdar Antagonist D L Apv, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmdar+antagonist+d+l+ap5/D-AP5/10__1523_slash_eneuro__0118___19__2019-72-8-13
    Average 96 stars, based on 1 article reviews
    nmdar antagonist d l apv - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    nmdar antagonist d l ap5  (Tocris)
    93
    Tocris nmdar antagonist d l ap5
    Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the <t>NMDAR</t> component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).
    Nmdar Antagonist D L Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmdar+antagonist+d+l+ap5/L-AP5/pmc04648633-234-14-19
    Average 93 stars, based on 1 article reviews
    nmdar antagonist d l ap5 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    nmdar antagonist d  (Tocris)
    92
    Tocris nmdar antagonist d
    Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the <t>NMDAR</t> component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).
    Nmdar Antagonist D, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmdar+antagonist+d+l+ap5/L-AP5/pmc02681441-113-4-14
    Average 92 stars, based on 1 article reviews
    nmdar antagonist d - by Bioz Stars, 2026-11
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the NMDAR component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).

    Journal: eneuro

    Article Title: Differences in GluN2B-Containing NMDA Receptors Result in Distinct Long-Term Plasticity at Ipsilateral versus Contralateral Cortico-Striatal Synapses

    doi: 10.1523/eneuro.0118-19.2019

    Figure Lengend Snippet: Figure 1. Morphologic and functional features of ipsilateral and contralateral cortico-striatal pathways. A, EYFP immunostaining shows the bilateral projection of M1 cortical neurons in the striatum. Asterisk shows the injection site of AAV-CaMKII-ChR2-EYFP in M1; white boxes in the ipsilateral and contralateral dorsolateral striatum are enlarged below. Scale bars: 500 m (top) and 50 m (bottom). B, Double VGLUT1 and EYFP immunostaining (left) shows co-localized puncta (arrowheads) in the striatum of both hemispheres, ipsilateral and contralateral to the AAV-CaMKII-ChR2-EYFP injection site in M1. Double VGLUT2 and EYFP immu- nostaining (right) shows a lack of co-localization. Scale bar: 5 m. C, Representative EPSCs (from D) evoked by blue light (470 nm) in ipsilateral (top) and contralateral (bottom) MSNs in striatal slices from mice expressing CaMKII-ChR2-EYFP in M1. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. D, Average of the NMDAR component of the blue light-evoked EPSC in ipsilateral and contralateral MSNs (n 9, Ipsi MSNs; n 7, Contra MSNs; p 0.0001, unpaired Student’s t test). E, Representative EPSCs (from F–H) evoked by blue light with different durations (1, 2, 3, and 4 ms) in ipsilateral (top) and contralateral (bottom) MSNs. MSNs were held at 60 mV and perfused with aCSF containing normal Mg2. Traces are from baseline, 10 min after NBQX, and 10 min after D,L-APV. F–H, I/O relationship between light pulse duration, and total EPSC amplitude (F; n 6, Ipsi MSNs; n 6, Contra MSNs; p 0.14, two-way ANOVA with Bonferroni post hoc tests) or NMDAR EPSC amplitude (G; p 0.036) or the ratio of NMDAR EPSC amplitude to total EPSC amplitude (H; p 0.0001).

    Article Snippet: NMDAR EPSCs were confirmed by addition of the NMDAR antagonist D,L-APV (20 M; Tocris, catalog #0106) at the end of the recordings.

    Techniques: Functional Assay, Immunostaining, Injection, Expressing

    Figure 2. Differences in subunit composition of synaptic NMDARs between the ipsilateral and contralateral cortico-striatal pathways. A, Double tdTomato and EGFP immunostaining shows segregation of D1 and D2 MSNs in the striatum of Drd1a-tdTomato::Drd2- EGFP double transgenic mice. B, Representative NMDAR EPSCs (from C) in D1 (top) and D2 MSNs (bottom) evoked by electrical stimulation of the cortico-striatal pathway. Traces are from baseline (1), 10 min after ifenprodil (2), 10 min after TCN-201 (3), and 10 min after D,L-APV. C, Average effects of ifenprodil, TCN-201, and D,L-APV on NMDAR EPSC amplitudes (n 7, D1 MSNs; n 6, D2 MSNs; p 0.56, two-way ANOVA). D, Representative EPSCs (from E) evoked by blue light in ipsilateral (top) and contralateral (bottom) MSNs. Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). E, Average effects of ifenprodil and TCN-201 on blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.0013, two-way ANOVA). F, Average percentage of the ifenprodil-sensitive and TCN-201-sensitive components of NMDAR-mediated EPSCs. The ifenprodil- sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in ifenprodil from baseline EPSCs; the TCN-201-sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in TCN-201 from EPSCs in the presence of ifenprodil (p 0.0001, unpaired Student’s t test). G, tdTomato and GFP immunostaining shows ipsilateral Chrimson expression and contralateral Chronos expression. Scale bars: 100 m (left) and 10 m (right). H, Representative EPSCs (from I) evoked by either Chrimson-activating red light (625 nm, top) or Chronos-activating blue light (470 nm, bottom). Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). l, Average effects of ifenprodil and TCN-201 on red light-evoked and blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.028, two-way ANOVA).

    Journal: eneuro

    Article Title: Differences in GluN2B-Containing NMDA Receptors Result in Distinct Long-Term Plasticity at Ipsilateral versus Contralateral Cortico-Striatal Synapses

    doi: 10.1523/eneuro.0118-19.2019

    Figure Lengend Snippet: Figure 2. Differences in subunit composition of synaptic NMDARs between the ipsilateral and contralateral cortico-striatal pathways. A, Double tdTomato and EGFP immunostaining shows segregation of D1 and D2 MSNs in the striatum of Drd1a-tdTomato::Drd2- EGFP double transgenic mice. B, Representative NMDAR EPSCs (from C) in D1 (top) and D2 MSNs (bottom) evoked by electrical stimulation of the cortico-striatal pathway. Traces are from baseline (1), 10 min after ifenprodil (2), 10 min after TCN-201 (3), and 10 min after D,L-APV. C, Average effects of ifenprodil, TCN-201, and D,L-APV on NMDAR EPSC amplitudes (n 7, D1 MSNs; n 6, D2 MSNs; p 0.56, two-way ANOVA). D, Representative EPSCs (from E) evoked by blue light in ipsilateral (top) and contralateral (bottom) MSNs. Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). E, Average effects of ifenprodil and TCN-201 on blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.0013, two-way ANOVA). F, Average percentage of the ifenprodil-sensitive and TCN-201-sensitive components of NMDAR-mediated EPSCs. The ifenprodil- sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in ifenprodil from baseline EPSCs; the TCN-201-sensitive component of the NMDAR EPSCs was calculated by subtracting EPSCs after 10 min in TCN-201 from EPSCs in the presence of ifenprodil (p 0.0001, unpaired Student’s t test). G, tdTomato and GFP immunostaining shows ipsilateral Chrimson expression and contralateral Chronos expression. Scale bars: 100 m (left) and 10 m (right). H, Representative EPSCs (from I) evoked by either Chrimson-activating red light (625 nm, top) or Chronos-activating blue light (470 nm, bottom). Traces are from baseline (1), 10 min after ifenprodil (2), and 10 min after TCN-201 (3). l, Average effects of ifenprodil and TCN-201 on red light-evoked and blue light-evoked NMDAR EPSCs (n 19, Ipsi MSNs; n 16, Contra MSNs; p 0.028, two-way ANOVA).

    Article Snippet: NMDAR EPSCs were confirmed by addition of the NMDAR antagonist D,L-APV (20 M; Tocris, catalog #0106) at the end of the recordings.

    Techniques: Immunostaining, Transgenic Assay, Expressing